anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to Chinese patent medicament for treating a mammary gland disease. The medicine comprises the following raw material medicaments in part by weight: 250 to 1500 parts of torrefied crab, 10 to 30 parts of Chinese eaglewood and 15 to 40 parts of sanchi. The medicine is prepared by: roasting a whole crab for 1 to 2 hours at a temperature between 80 and 200 DEG C; crushing the whole crab, and passing an 80 to 120-mesh screen; and evenly mixing crab powder with other components to prepare powders. Practice proves that the medicament is reasonable in compatibility and good in synergy effect, can treat both tip and root, can effectively treat diseases such as mastocarcinoma, acute and chronic mastitis and the like, and has the cure rate over 90 percent for treating the mastocarcinoma and the cure rate over 95 percent for people with the mastitis and mammary gland hyperplasia. The disease is not easy to relapse after being cured, and the effect is good. The Chinese patent medicament has the advantages of simple formula, low cost, fewer expenses of the patients, medication safety and no toxic or side effects, and is easy to be accepted by the patients.
Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
Embodiments described herein generally relate to articles and methods for containing compositions comprising hydrogen gas. In some embodiments, the article comprises a container that comprises glass. In some cases, the container may further comprise TiO2, which may be embedded within the glass, coated on the glass, etc. The container further may contain a composition within the container. In some cases, the composition may comprise dissolved hydrogen gas. Such compositions may be useful, for example, for the treatment of animal and human diseases, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like.
PURPOSE:To improve the skin washing effect, enzymic stability and feeling of use, by using a proteolytic enzyme derived from microorganisms as an enzyme in producing a face washing powder containing talc, etc. as a base material. CONSTITUTION:(b) Sodium polyacrylate, (c) a surfactant, e.g. monosodium N- lauryl-L-glutamate, as a detergent and (d) a proteolytic enzyme derived from microorganisms, e.g. ASP-, actionmyces-, black KOJI mold-protease, etc. are incorporated in (a) a base material, e.g. corn starch or talc, and (e) a perfume is further added thereto to give a face washing powder containing the enzyme. The above-mentioned powder is capable of washing the skin fully with the component (d), and the water absorbing property of the component (b) stabilizes the component (d). Thus, the deterioration in detergency with time can be prevented. The smooth foaming in use by the component (b) eases the sandiness of the talc and improves the feeling of use.
The present invention describes a method which outlines a process for conversion of CBD to a Δ 9 -tetrahydrocannabinol (Δ 9 -THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the Δ 9 -tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% Δ 9 -THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce Δ 9 -THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% Δ 9 -THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the Δ 9 -THC using distillation and collecting an essentially pure fraction of Δ 9 -THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity Δ 9 -THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.
Psychiatric disorders frequently co-occur and share common symptoms and genetic backgrounds. Previous research has used genome-wide association studies to identify the interrelationships among psychiatric disorders and identify clusters of disorders; however, these methods have limitations in terms of their ability to examine the relationships among disorders as a network structure and their generalizability to the general population. In this study, we explored the network structure of the polygenic risk score (PRS) for 13 psychiatric disorders in a general population (276,249 participants of European ancestry from the UK Biobank) and identified communities and the centrality of the network. In this network, the nodes represented a PRS for each psychiatric disorder and the edges represented the connections between nodes. The psychiatric disorders comprised four robust communities. The first community included attention-deficit hyperactivity disorder, autism spectrum disorder, major depressive disorder, and anxiety disorder. The second community consisted of bipolar I and II disorders, schizophrenia, and anorexia nervosa. The third group included Tourette's syndrome and obsessive-compulsive disorder. Cannabis use disorder, alcohol use disorder, and post-traumatic stress disorder make up the fourth community. The PRS of schizophrenia had the highest values for the three metrics (strength, betweenness, and closeness) in the network. Our findings provide a comprehensive genetic network of psychiatric disorders and biological evidence for the classification of psychiatric disorders.
Obesity and type 2 diabetes (T2D) are widespread metabolic disorders that significantly impact global health today, affecting approximately 17% of adults worldwide with obesity and 9.3% with T2D. Both conditions are closely linked to disruptions in lipid metabolism, where peroxisomes play a pivotal role. Mitochondria and peroxisomes are vital organelles responsible for lipid and energy regulation, including the β-oxidation and oxidation of very long-chain fatty acids (VLCFAs), cholesterol biosynthesis, and bile acid metabolism. These processes are significantly influenced by estrogens, highlighting the interplay between these organelles' function and hormonal regulation in the development and progression of metabolic diseases, such as obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and T2D. Estrogens modulate lipid metabolism through interactions with nuclear receptors, like peroxisome proliferator-activated receptors (PPARs), which are crucial for maintaining metabolic balance. Estrogen deficiency, such as in postmenopausal women, impairs PPAR regulation, leading to lipid accumulation and increased risk of metabolic disorders. The disruption of peroxisomal-mitochondrial function and estrogen regulation exacerbates lipid imbalances, contributing to insulin resistance and ROS accumulation. This review emphasizes the critical role of these organelles and estrogens in lipid metabolism and their implications for metabolic health, suggesting that therapeutic strategies, including hormone replacement therapy, may offer potential benefits in treating and preventing metabolic diseases.
PURPOSE:To provide a new compound useful as pharmaceuticals such as antibacterial agent and an external agent for suppressing melanogenesis. CONSTITUTION:The compound of formula (R is 3-19C saturated or unsaturated straight or branched-chain hydrocarbon group), e.g. glabridin undecylenic acid diester. The compound can be produced by condensing glabridin to a specific straight or branched-chain 4-20C fatty acid in an organic solvent (e.g. chloroform) using N,N-dicyclohexylcarbodiimide or 4-dimethylaminopyridine. The compound is colorless transparent oil having excellent solubility in alcohols, etc.
FIELD: medicine, urology, pharmacy. SUBSTANCE: antibacterial agent is made as the solid medicinal form that consists of core and envelope. Core has nitroxoline as an active component and aerosil, starch, lactose and slipping substances as special additions. Core has the following components, wt. -%: nitroxoline, 38.0-62.0; aerosil, 1.0-10.0; starch, 12.0-30.0; lactose, 12.0-30.0; slipping substances, 1.0-4.0. Envelope consists of sugar, magnesium base carbonate, aerosil, talc, titanium dioxide, polyvinylpyrrolidone, dye and polishing substances. Method of agent making involves wetting mixture of active component with special additions and slipping substances, granulation, drying, dry granulation, core formation and application of envelope on core by layers. Envelope layers have sugar, magnesium base carbonate, aerosil, talc, titanium dioxide, polyvinylpyrrolidone and mixture of sugar, dye and polishing substances in series. Preparation shows stability and releases the active component in gastroenteric tract rapidly. Invention can be used for treatment of patients with infections of urogenital ways (pyelonephritis, cystitis, prostatitis) and prophylaxis of infections after surgery in kidney and urinary ways. EFFECT: enhanced effectiveness of agent, improved method of preparing. 7 cl, 1 tbl, 4 ex
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable ox specifically and effectively inhibiting the reduction of the immunological function of the skin by ultraviolet rays, capable of maintaining the immunological function in a normal state, and hardly accompanying a topical or constitutional side effect by including a lipoic acid. SOLUTION: The objective inhibitor contains one or more kinds selected from a group of lipoic acid, its salt and its derivative, or one or more kinds of extracts of plants preferably belonging to the genus Pisum. A sodium salt is cited as the salt of the lipoic acid, and alkyl esters are cited as the derivative of the lipoic acid. The proportion of the added inhibitor to a substrate or a carrier is preferably 0.001-5.0 wt.% based on the whole weight. Pisum sativum L. var. arvense Poir. and Pisum sativum L. are cited as the plant belonging to the genus Pisum. The extraction is carried out by dipping the plant in an extraction solvent. The extraction can be carried out while stirring or homogenizing the plant in the extraction solvent (e.g. water and methanol). The extraction temperature is preferably from 5 deg.C to the boiling point of the extraction solvent.
PURPOSE:To provide the titled remedy having high safety, free of side effects, and useful for the remedy of myelocytic leukemia, by using an iodine salt which liberates iodine ion in water, as an active component. CONSTITUTION:The objective remedy contains, as an active component, an iodine salt which liberates iodine ions in water[e.g. alkali metal salt (sodium salt,  potassium salt, etc.) and an alkaline earth metal salt (magnesium salt, calcium salt, etc.)]. Myelocytic leukemia is a disease caused by the unrestrained proliferation of myelocytes having high heteromorphism. The tumorous proliferation  of promyelocytic cell is characterized by the remarkable tendency of hemorrhage and rapid progress. The iodine salt remarkably inhibits the tumorous proliferation of promyelocytic cell, and its mechanism is supposed that hypoiodous ions are produced according to the increase of peroxidase (PO) in the myelocytic cell, and the ion promotes the production of tumoricidal leukocytes.
Eating disorders (EDs) are serious illnesses with highest incidence in adolescents. Moreover, athletes have a higher frequency of symptoms of disordered eating (DE) and EDs than non-athletes. There are many reasons to this health issue, but body appearance pressure, competing in body mass sensitive sports, and comments on body appearance are important explanations. Few programs have proved effective in preventing DE and EDs in the general population, or in athletes specifically, and none is permanent operative in sports in Norway. Body Project by prof Eric Stice have proved effective in preventing body dissatisfaction, figure idealization and new onset of EDs in female adolescents above 15 years of age, and with body dissatisfaction, from the general population. A few attempts to adapt this program to female athletes, argue for a comparative positive effect. Three important elements to further address, are: 1) programs need also to be tested in males; 2) programs need to be tested in adolescents of younger age before the typical onset of an ED; and 3) programs need to be possible to administer by non-professionals.

In this study the research group aim to adapt and test the effect of the Body Project, by the pilot study the "Healthy Sport Project", in elite junior athletes attending specialized junior sport high schools (age 14). The final goal for this project group is to create an effective preventive program for body dissatisfaction and DE/EDs in young athletes of both sexes and in mixed sports, and which may be administered by the schoolteachers.
BACKGROUND: Exploring the value of baseline and early 18F-FDG PET/CT evaluations in prediction PFS in ER+/HER2- metastatic breast cancer patients treated with a cyclin-dependent kinase inhibitor in combination with an endocrine therapy.
METHODS: Sixty-six consecutive breast cancer patients who underwent a pre-therapeutic 18F-FDG PET/CT and a second PET/CT within the first 6 months of treatment were retrospectively included. Metabolic tumour volume (MTV) and total lesion glycolysis (TLG) and Dmax, which represents tumour dissemination and is defined as the distance between the two most distant lesions, were computed. The variation in these parameters between baseline and early evaluation PET as well as therapeutic evaluation using PERCIST were assessed as prognosticators of PFS at 18 months.
RESULTS: The median follow-up was equal to 22.5 months. Thirty progressions occurred (45.4%). The average time to event was 17.8 ± 10.4 months. At baseline, Dmax was the only predictive metabolic parameter. Patients with a baseline Dmax ≤ 18.10 cm had a significantly better 18 m-PFS survival than the others: 69.2% (7.7%) versus 36.7% (8.8%), p = 0.017. There was no association between PERCIST evaluation and 18 m-PFS status (p = 0.149) and there was no difference in 18 m-PFS status between patients classified as complete, partial metabolic responders or having stable metabolic disease.
CONCLUSION: Disease spread at baseline PET, as assessed by Dmax, is predictive of an event occurring within 18 months. In the absence of early metabolic progression, which occurs in 15% of patients, treatment should be continued regardless of the quality of the initial response to treatment.
This is a randomized control trial evaluating power seat function usage among 3 groups: 1) standard of care- verbal instruction 2) verbal and written instruction and 3) same as #2 with addition of virtual coach. This study will be conducted in two phases. Phase I data will be collected for 8 weeks, during the time period that the subject is awaiting for delivery of their personal electric powered wheelchair (EPW) with powered seat functions. Phase II data will be collected for a total of 4 weeks, after the subject receives their personal wheelchair. During Phase I, Visit I, subjects will be fitted for a study EPW with powered seat functions. All subjects will be provided with the "standard of care" training on driving of the wheelchair and usage of the power seating functions. Subjects will be instructed to go about their daily activities as they normally would, while the instrumented wheelchair will track their usage of the wheelchair and seating habits. Phase I, Visit II-IV, subjects will be randomized into one of three study groups: Control Group; Instruction Group; and Instruction \& Virtual Coach Group. Subjects assigned to the Control Group will receive 'standard of care.' Subjects assigned to the Intervention Group will receive the "standard of care" and additional written instructional materials and feedback regarding activity and wheelchair usage. Subjects assigned to the Instruction \& Virtual Coach Group will receive the same training and instructional materials as the Intervention Group. This group will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. Phase II will involve mounting a wheelchair and seat function usage datalogger to the subject's personal wheelchair over a period of 4 weeks.
The remobilization of stored assimilates from stems to seeds plays a pivotal role in augmenting barley yield, particularly under water stress conditions. This study examines the molecular mechanisms underlying stem reserve utilization by conducting a comparative analysis of the proteome and metabolome across three barley contrasting genotypes: Yousef, Morocco, and PBYT17. Evaluations were performed at 21 and 28 days after anthesis (DAA) under both water stress and control conditions. The results indicate that the Yousef genotype exhibits superior remobilization of stem reserves, thereby demonstrating its potential to thrive even in adverse environmental conditions. Utilizing advanced quantitative proteomics and targeted metabolomics, this investigation identified a significant number of metabolites and proteins exhibiting differential accumulation across the genotypes. Specifically, 17 metabolites and 1580 proteins were catalogued, highlighting the intricate biochemical responses to water stress. Noteworthy enzymes such as sucrose synthase, inositol monophosphatase 3, and galactokinase were found to be closely associated with remobilization efficiency. In the drought-tolerant genotype, these enzymes maintained stable levels, in stark contrast to the decline observed in the susceptible genotype. This stability is crucial for promoting seed development through ascorbic acid synthesis and for mitigating oxidative stress, which is exacerbated by drought conditions. The elevated levels of certain metabolites, including glucose 6-phosphate, and UDP-glucose, in the drought-tolerant genotype suggest a robust mechanism for maintaining signalling molecules for carbon availability, which is then instrumental in regulating plant growth and seed size development. The findings from this study strongly imply that the drought-tolerant genotype, through enhanced antioxidant capacity, can effectively produce energy-rich storage compounds, thereby optimizing carbon allocation under water stress. Such insights are invaluable for future breeding strategies aimed at improving barley resilience in the face of climate variability.
Participants will receive Treatment A (AG-881 Formulation 1, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 1) followed by Treatment B (AG-881 Formulation 2, 50 mg, tablet orally, under fasted condition once on Day 1 of Period 2) followed by Treatment C (AG-881 Formulation 2, 50 mg, tablet, orally, under fed condition once on Day 1 of Period 3) followed by Treatment D (omeprazole 40 mg capsule, orally, once daily on Days 1 to 4 and AG-881 Formulation 2, 50 mg, tablet, orally, under fasted condition, once on Day 4 of Period 4). Each period will be separated by a Washout Period of 21 days.
The WLC control condition entails following usual care and includes the ability to participate in the intervention at the 12 week-end point for the intervention group. The WLC condition is based on equity considerations; the investigators want all participants to have access to treatment. Equity is especially important given our plans to over-enroll African American persons given statistically increased barriers to access care.
Cephalosporins of formula (I) are new together with their salts and esters (where A is pyridyl opt. substd. by Cl or Br, phenyl or phenylalkyl in which the phenyl gps. are opt. substd. by alkyl, alkoxy, halo, CF3, NO2, or oh; R is H, acetoxy, carbamoxyloxy, pyridinium or heterocyclylthio). (I) are broad-spectrum antibacterial agents for use as disinfectants and as animal feed supplements as well as their primary use in treating infections.
This study explores the bidirectional association between multimorbidity and falls in Chinese middle-aged and elderly adults. Participants aged 45 and above from the China Health and Retirement Longitudinal Study were included. Binary logistic regression assessed the impact of chronic conditions on fall incidence (stage I), while multinomial logistic regression examined the relationship between baseline falls and multimorbidity (stage II). The fully adjusted odds ratios (ORs) for one, two, or three or more chronic conditions were 1.34, 1.65, and 2.02, respectively. Among participants without baseline falls, 28.61% developed two or more chronic conditions during follow-up, compared to 37.4% of those with a history of falls. Fully adjusted ORs for one, two, or three or more chronic conditions in those with a history of falls were 1.21, 1.38 and 1.70, respectively. The bidirectional relationship held in sensitivity and subgroup analyses. A bidirectional relationship exists between multimorbidity and falls in Chinese middle-aged and elderly adults. Strengthening chronic condition screening and treatment in primary healthcare may reduce falls risk, and prioritizing fall prevention and intervention in daily life is recommended.